The clinical utility in hospital‐wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA ‐related disorders
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.12821 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Andrea Cortés Fernández und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Mitochondrial Diseases, DNA, Mitochondrial, Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Children's Hospital Colorado Foundation, National Institute of Neurological Disorders and Stroke (NINDS).
Abstract (Originalsprache)
Clinical recognition of primary mitochondrial disorders (PMD) is difficult due to the clinical and genetic heterogeneity. Whereas lactate has low sensitivity and specificity, in structured clinical studies growth differentiation factor 15 (GDF15) has shown promise with elevations in mitochondrial DNA (mtDNA)‐related PMD, but its specificity has been questioned. In a tertiary care hospital‐wide study, medical records were retrospectively reviewed from 418 cases where GDF15 levels were obtained by clinicians. Patients were classified into patients with PMD due to mtDNA‐related defects (mtDNA maintenance, mtDNA deletions, and mtDNA‐encoded tRNA variants), PMD due to structural defects or other nuclear causes, and in non‐mitochondrial disease. Patients with liver disease or systemic critical illness were excluded. GDF15 was assayed in a clinical laboratory with a cutoff of 750 ng/L. There were 38 mtDNA‐related PMD (GDF15 >750 pg/mL in 76%), 35 other nuclear DNA‐encoded PMD or structural subunits (31% elevated GDF15), 309 non‐mitochondrial disorders (13% elevated GDF15). Based on the highest Youden J‐index, the optimal cut‐off value to identify these target mtDNA‐related disorders was 815 pg/mL, with sensitivity 76%, specificity 88%, positive predictive value of 41% and negative predictive value of 97%. At this optimized cutoff level, mtDNA‐encoded PMD patients had elevated GDF15 in 76%, nuclear DNA‐encoded PMD in 26%, and non‐mitochondrial disorders in 11% of patients. Thus, in a real‐life clinical setting, after excluding abnormal liver function and critical illness, GDF15 had good clinical utility increasing the odds at predicting mtDNA‐related primary mitochondrial disorders 14‐fold, but not for structural or other nuclear‐encoded primary mitochondrial disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado, Aurora, Colorado, USA.
- Department of Diagnostic Genomics, PathWest Laboratory Medicine WA, Nedlands, Western Australia, Australia.
- Department of Laboratory Medicine and Pathology, Mayo Clinic School of Medicine, Rochester, Minnesota, USA.
ORCID-Profile: Andrea Cortés Fernández, Jane Estrella, Devin Oglesbee, Austin A Larson, Johan L K Van Hove
Förderung
- NINDS NIH HHS
- Children's Hospital Colorado Foundation
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Colorado Foundation
Zitieren
APA
Fernández, A. C., Estrella, J., Oglesbee, D., Larson, A. A., & Van Hove, J. L. K. (2025). The clinical utility in hospital‐wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA ‐related disorders. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12821
Vancouver
Fernández AC, Estrella J, Oglesbee D, Larson AA, Van Hove JLK. The clinical utility in hospital‐wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA ‐related disorders. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.12821
BibTeX
@article{Fernndez2025,
author = {Fernández, Andrea Cortés and Estrella, Jane and Oglesbee, Devin and Larson, Austin A and Van Hove, Johan L K},
title = {The clinical utility in hospital‐wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA ‐related disorders},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.12821}
}
EUVIMED